Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2019

View Archived Issues

Loss of function of ADAR1 in tumor cells as a new strategy to overcome immunotherapy resistance

Nanoscavenger versus neurotoxins

Chemotherapy can facilitate metastases

Mavupharma names its first immuno-oncology clinical development candidate

AbbVie and Tizona Therapeutics to jointly develop CD-39-targeted therapeutics

NLRC5, a new diagnostic marker of IgA nephritis and its progression

Bionomics initiates phase II MODULATE study of BNC-105 in combination with nivolumab

Lundbeck initiates phase II study of Lu-AF-11167 for the treatment of schizophrenia

Obesity may be linked to anxiety via senescence

Pse-T2 shows promising activity in a mouse wound model infected with MDR strains

Positive topline results presented from first cohort of phase I/II study of DTX-401

CHDI-390576, a novel CNS-penetrant benzhydryl hydroxamic acid class IIa HDAC inhibitor

Phase I results reported for oral ferroportin inhibitor VIT-2763

Gilead and Yuhan enter licensing and collaboration agreement to treat NASH-related fibrosis

PRKCD targeting found useful against EGFR inhibitor-resistant lung cancer

Galapagos initiates phase I trial with GLPG-3312

Valneva announces promising phase I interim data on Chikungunya vaccine candidate VLA-1553

Galapagos initiates phase IIa study of GLPG-1690 in systemic sclerosis

Jazz and Codiak collaborate on exosome therapeutics to treat cancer

FDA clears IND for phase I trial of ARV-110 in metastatic castration-resistant prostate cancer

Adaptive Biotechnologies and Genentech collaborate on neoantigen-directed T-cell cancer therapies

Regulus reports preliminary interim data from mouse chronic toxicity study of RGLS-4326

KCI-807 compound discovered as an androgen receptor function disruptor in prostate cancer

Idorsia begins multiple-dose study of cenerimod for SLE

Sojournix completes financing to advance SJX-653 for menopausal vasomotor symptoms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...